Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-159. (Canceled)

160. (Currently Amended) A compound of formula (I), or a solvate or pharmaceutically acceptable salt thereof:



(I)

wherein, ~~independently at each occurrence,~~

X is selected from $-C(R_6,R_{14})-Y-$, and $-C(R_{13})=CH-$;

Y is selected from a direct bond, O, S, and C_1-C_4alkylene;

R_{13} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl, and benzyl;

R_1 and R_2 ~~, when~~ taken together with the nitrogen atom to which they are directly attached in formula (I) form a morpholinyl ring ~~, form a ring denoted by formula (II):~~



~~(II)~~

~~wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and~~ where any one or more of the ~~additional~~ carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, and C_1-C_{20}alkanoyloxy; ~~, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur; and any two adjacent additional carbon ring atoms may be fused to a C_3-C_8carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from hydrogen, C_1-C_6alkyl, C_2-C_4acyl, C_2-C_4hydroxyalkyl and C_3-C_8alkoxyalkyl; or~~

~~R_1 and R_2, when taken together with the nitrogen atom to which they are directly attached in formula (I), may form a bicyclic ring system selected from 3-azabicyclo[3.2.2]nonan-3-yl, 2-azabicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]hexan-3-yl, and 3-azabicyclo[3.2.0]heptan-3-yl;~~

R_3 and R_4 are independently attached to the cyclohexane ring shown in formula (I) at the 3-, 4-, 5- or 6- positions and are independently selected from hydrogen, hydroxy, C_1-C_6alkyl, and C_1-C_6alkoxy;

R_5, R_6 and R_{14} are independently selected from hydrogen, C_1-C_6alkyl, aryl and benzyl;

A is selected from C_5-C_{12}alkyl, a C_3-C_{13}carbocyclic ring, and ring systems selected from formulae (III), (IV), (V), (VI), (VII) and (VIII):



(III)

where R_7, R_8 and R_9 are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl,

C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(IV)

and



(V)

where R_{10} and R_{11} are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(VI)

where R_{12} is selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl; and Z is selected from CH, CH_2, O, N and S, where Z may be directly bonded to "X" as shown in formula (I) when Z is CH or N, or Z may be directly bonded to R_{17} when Z is N, and R_{17} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl and benzyl;



(VII)

and



(VIII)

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

161. (Currently Amended) A compound according to claim 160 having formula (IX), or a solvate or pharmaceutically acceptable salt thereof:



(IX)

wherein, ~~independently at each occurrence,~~

X is selected from $-C(R_6,R_{14})-Y-$, and $-C(R_{13})=CH-$;

Y is selected from a direct bond, O and S; and

R_1, R_2, R_3, R_4, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{14}, A and Z are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

162. (Currently Amended) A compound of claim 160 having formula (X), or a solvate or pharmaceutically acceptable salt thereof:



(X)

wherein, ~~independently at each occurrence,~~

X is selected from $-C(R_6,R_{14})-Y-$, and $-C(R_{13})=CH-$;

Y is selected from a direct bond, O, and S;

R_1, R_2, R_6 and R_{14} are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and C_1-C_6alkoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V), and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

163. (Currently Amended) A compound of claim 160 having formula (XI), or a solvate or pharmaceutically acceptable salt thereof:



(XI)

wherein, ~~independently at each occurrence,~~

R_1 and R_2 are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V), and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

164. (Currently Amended) A compound of claim 160 having formula (XII), or a solvate or pharmaceutically acceptable salt thereof:



(XII)

wherein, ~~independently at each occurrence,~~

R_1 and R_2 are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

165. (Currently Amended) A compound of claim 160 having formula (XIII), or a solvate or pharmaceutically acceptable salt thereof:



(XIII)

wherein, ~~independently at each occurrence,~~

X is selected from -C(R_6,R_{14})-Y- and -CH=CH-;

Y, R_1, R_2, R_6 and R_{14} are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_3-C_8cycloalkyl and any of formulae (III), (IV), (V), (VI), (VII) and (VIII) as defined in claim 160, where R_8 and R_9 are defined as in claim 160 ~~49~~, R_7, R_{10}, R_{11} and R_{12} are hydrogen, and Z is selected from O, S and N-R_{17} where R_{17} is selected from hydrogen and methyl;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

166. (Currently Amended) A compound of claim 160 having formula (XIV), or a solvate or pharmaceutically acceptable salt thereof:



(XIV)

wherein, ~~independently at each occurrence,~~

R_1 and R_2 are defined as in claim 160; and

A is selected from any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein R_7, R_{10}, R_{11} and R_{12} are hydrogen, R_8 and R_9 are independently selected from hydrogen, hydroxy, fluorine, chlorine, bromine, methanesulfonamido, methanoyloxy, methoxycarbonyl, nitro, sulfamyl, thiomethyl, trifluoromethyl, methyl, ethyl, methoxy, ethoxy and NH_2; and Z is selected from O and S;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

167. (Currently Amended) A compound of claim 160 having formula (XV), or a solvate or pharmaceutically acceptable salt thereof:



(XV)

wherein, ~~independently at each occurrence,~~

R_1 and R_2 are defined as in claim 160; and

A is selected from any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein R_7, R_{10}, R_{11} and R_{12} are hydrogen, R_8 and R_9 are independently selected from hydrogen, hydroxy, fluorine, chlorine, bromine, methanesulfonamido, methanoyloxy, methoxycarbonyl, nitro, sulfamyl, thiomethyl, trifluoromethyl, methyl, ethyl, methoxy, ethoxy and NH_2; and Z is selected from O and S;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

168. (Currently Amended) A compound of claim 160 having formula (XVI), or a solvate or pharmaceutically acceptable salt thereof:



(XVI)

wherein, ~~independently at each occurrence,~~

X is selected from *trans*-CH=CH-, $-CH_2-$ and $-CH_2-O-$;

R_1 and R_2 taken together with the nitrogen atom to which they are attached form ~~a ring selected from pyrrolidinyl, 2-ketopyrrolidinyl, 3-ketopyrrolidinyl, 2-acetoxypyrrolidinyl, 3-acetoxypyrrolidinyl, 2-hydroxypyrrolidinyl, 3-hydroxypyrrolidinyl, thiazolidinyl, piperidinyl, 2-ketopiperidinyl, 3-ketopiperidinyl, 4-ketopiperidinyl,acetylpiperazinyl, 1,4-dioxa-7-azaspiro[4.4]non-7-yl, hexahydroazepinyl,~~ morpholinyl ~~, N-methylpiperazinyl and 3-azabicyclo[3.2.2]nonanyl~~; and

A is selected from cyclohexyl, monochlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2-bromophenyl, 2,4-dibromophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dimethoxyphenyl, 1-naphthyl, 2-naphthyl, 3-benzo(b)thiophenyl, 4-benzo(b)thiophenyl, (2-trifluoromethyl)phenyl, 2,4-di(trifluoromethyl)phenyl, and (4-trifluoromethyl)phenyl;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

169. (Currently Amended) A compound, or mixture comprising compounds, selected from the group consisting of:

(+)-*trans*-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(1-naphthenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(1-naphthenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(4-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(4-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-[2-(4-bromophenoxy)ethoxy]]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-[2-(4-bromophenoxy)ethoxy]]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3,4-dimethoxyphenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3,4-dimethoxyphenethoxy)]cyclohexane;

~~(+)-*trans*-[2-(1-pyrrolidinyl)-1-(1-naphthenethoxy)]cyclohexane;~~

~~(-)-*trans*-[2-(1-pyrrolidinyl)-1-(1-naphthenethoxy)]cyclohexane;~~

(+)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-3-yl)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-3-yl)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-4-yl)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-4-yl)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(2-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3-(3,4-dimethoxyphenyl)-1-propoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3-(3,4-dimethoxyphenyl)-1-propoxy)]cyclohexane;

(1R,2R)/(1S,2S)-2-(4-morpholinyl)-1-(3,4-dichlorophenethoxy)cyclohexane;

~~(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(1-acetylpiperazinyl)-1-(2-naphthenethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexane;~~

(1R,2S)/(1S,2R)-2-(4-morpholinyl)-1-[(2-trifluoromethyl)phenethoxy]cyclohexane;

~~(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-[3-(cyclohexyl)propoxy]cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(3-acetoxypyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(3-hydroxypyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(2,2-diphenylethoxy)cyclohexane;~~

~~(1R,2R)/(1S,2S)-2-(3-thiazolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane; and~~

~~(1R,2S)/(1S,2R)-2-(3-ketopyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane; and~~

including isolated enantiomeric and diastereomeric isomers thereof, and mixtures thereof; and pharmaceutically acceptable salts thereof.

170. (Previously Presented) A composition comprising a compound according to any one of claims 160-169 in combination with a pharmaceutically acceptable carrier, excipient or diluent.